Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 159   

Articles published

GSK 1,393.58 +4.58 (0.33%)
price chart
Is It Time To Sell AstraZeneca plc And Buy GlaxoSmithKline plc?
So the heyday of the pharmaceutical industry is over. Many blockbuster drugs have tumbled over the patent cliff, and there are now a range of 'me-too' drugs which produce a fraction of the revenues of the big drugs of yesteryear.
4 Payout Plays To Plough Your Cash Into: BT Group plc, GlaxoSmithKline plc ...
On first look BT (LSE: BT-A) may not be the most appetising payout pick out there, the firm having lagged the average market yield for some time now.
How Safe Is GlaxoSmithKline plc's 6% Dividend Yield?
At present, the company's shares yield just under 6%, around double the market average, making them extremely attractive in the current interest rate environment.
Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than ...
Although GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has struggled to grow its net profit in recent years, that situation is set to change.
GlaxoSmithKline plc (ADR) (GSK) Q2 Revenues Rise, Beat Expectations
British pharmaceutical giant GlaxoSmithKline plc (ADR) (NYSE:GSK) announced second-quarter fiscal'15 earnings before the market opened today, reporting better-than-expected earnings and revenues.
GlaxoSmithKline plc (GSK) Posts Earnings Results  Dakota Financial News
Stock in Focus - GlaxoSmithKline PLC (NYSE:GSK)  Vanguard Tribune
Credit Suisse Reiterates "Underperform" Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its “underperform” rating reaffirmed by Credit Suisse in a note issued to investors on Wednesday, Market Beat Ratings reports.
GlaxoSmithKline plc Plans Dividend of GBX 19 (GSK)  Dakota Financial News
GlaxoSmithKline plc given a 5.4% Potential Decrease Suggested by JP Morgan ...  DirectorsTalk Interviews
Q3 Earnings of $0.64 Expected for GlaxoSmithKline PLC (NYSE:GSK)
Sell-side Wall Street analysts are anticipating GlaxoSmithKline PLC (NYSE:GSK) will post a current quarter earnings per share of $0.64.
GlaxoSmithKline plc (GSK) - Investment Analysts' Recent Ratings Changes
7/23/2015 - GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at AlphaValue. They now have a GBX 1,732 ($26.88) price target on the stock.
GlaxoSmithKline plc Stock Rating Reaffirmed by AlphaValue (GSK)  The Legacy
GlaxoSmithKline plc's Buy Rating Reiterated at AlphaValue (GSK)  Mideast Time
Tired Of BT Group plc, Vodafone Group plc & AstraZeneca plc? Snap Up ...
If you're tired of BT (LSE: BT-A), Vodafone (LSE: VOD) and AstraZeneca (LSE: AZN), then GlaxoSmithKline (LSE: GSK) and Unilever (LSE: ULVR) could be valid alternatives at their current levels. Here's my quick take on these five behemoths.
GlaxoSmithKline plc Receives "Overweight" Rating from Barclays (GSK)
Barclays restated their overweight rating on shares of GlaxoSmithKline plc (LON:GSK) in a report issued on Tuesday, Analyst Ratings Net reviews.
Shares of GlaxoSmithKline PLC (NYSE:GSK) Sees Large Inflow of Net Money Flow  Money Flow Index
Large Inflow of Money Witnessed in GlaxoSmithKline PLC  American Trade Journal